BACKGROUND: Sustained atrial fibrillation (AF) is a common risk factor for stroke. While intermittent AF also appears to pose a substantial stroke risk, the quantitative relationship between the percentage of time spent in AF and stroke risk is poorly specified and "intermittent" AF is not the same as paroxysmal AF. Improved assessment of the impact of AF burden on stroke risk will allow more targeted and safer use of antithrombotic therapy. METHODS AND RESULTS: The primary objective of this study is to determine if AT/AF (all device detected atrial tachyarrhythmias, including atrial flutter, atrial fibrillation, and atrial tachycardia) burden over a 30 day period is an independent predictor of the occurrence of ischemic stroke, transient ischemic attack (TIA) and/or systemic embolism in subjects not receiving anticoagulation therapy. TRENDS is a prospective, post-market, non-randomized, multicenter study designed to enroll 3100 subjects who have an independent Class I/II indication for cardiac rhythm device implantation and who have demographic features suggestive of an increased risk for thromboembolic complications related to AT/AF. All implanted devices will have the ability to collect long-term AT/AF burden trending data and will be equivalently programmed to ensure consistent data collection. All subjects will be followed with device interrogations every 3 months and clinic visits every 6 months for 1 year. Subjects with a documented history of AT/AF prior to enrollment and those who develop AT/AF during the 12-month follow-up will be followed until the last subject enrolled in the study has completed their 24-month follow-up. CONCLUSIONS: The results of the TRENDS study should help clarify the implications of data retrieved from an implantable device with regard to the risk for thromboembolic complications from atrial arrhythmias, even in the absence of symptoms.
BACKGROUND: Sustained atrial fibrillation (AF) is a common risk factor for stroke. While intermittent AF also appears to pose a substantial stroke risk, the quantitative relationship between the percentage of time spent in AF and stroke risk is poorly specified and "intermittent" AF is not the same as paroxysmal AF. Improved assessment of the impact of AF burden on stroke risk will allow more targeted and safer use of antithrombotic therapy. METHODS AND RESULTS: The primary objective of this study is to determine if AT/AF (all device detected atrial tachyarrhythmias, including atrial flutter, atrial fibrillation, and atrial tachycardia) burden over a 30 day period is an independent predictor of the occurrence of ischemic stroke, transient ischemic attack (TIA) and/or systemic embolism in subjects not receiving anticoagulation therapy. TRENDS is a prospective, post-market, non-randomized, multicenter study designed to enroll 3100 subjects who have an independent Class I/II indication for cardiac rhythm device implantation and who have demographic features suggestive of an increased risk for thromboembolic complications related to AT/AF. All implanted devices will have the ability to collect long-term AT/AF burden trending data and will be equivalently programmed to ensure consistent data collection. All subjects will be followed with device interrogations every 3 months and clinic visits every 6 months for 1 year. Subjects with a documented history of AT/AF prior to enrollment and those who develop AT/AF during the 12-month follow-up will be followed until the last subject enrolled in the study has completed their 24-month follow-up. CONCLUSIONS: The results of the TRENDS study should help clarify the implications of data retrieved from an implantable device with regard to the risk for thromboembolic complications from atrial arrhythmias, even in the absence of symptoms.
Authors: Alessandro Capucci; Massimo Santini; Luigi Padeletti; Michele Gulizia; GianLuca Botto; Giuseppe Boriani; Renato Ricci; Stefano Favale; Francesco Zolezzi; Natale Di Belardino; Giulio Molon; Fabrizio Drago; Giovanni Q Villani; Elena Mazzini; Marco Vimercati; Andrea Grammatico Journal: J Am Coll Cardiol Date: 2005-10-24 Impact factor: 24.094
Authors: Arnold J Greenspon; Robert G Hart; David Dawson; Anne S Hellkamp; Marc Silver; Greg C Flaker; Eleanor Schron; Lee Goldman; Kerry L Lee; Gervasio A Lamas Journal: J Am Coll Cardiol Date: 2004-05-05 Impact factor: 24.094
Authors: Alan S Go; Kristi Reynolds; Jingrong Yang; Nigel Gupta; Judith Lenane; Sue Hee Sung; Teresa N Harrison; Taylor I Liu; Matthew D Solomon Journal: JAMA Cardiol Date: 2018-07-01 Impact factor: 14.676
Authors: Michael H Kim; Michael J Reiter; Robert Canby; Anthony Navone; Te-Hsin Lung; Julie Pfeiffer Journal: J Interv Card Electrophysiol Date: 2010-06-04 Impact factor: 1.900
Authors: Andrea Ballatore; Mario Matta; Andrea Saglietto; Paolo Desalvo; Pier Paolo Bocchino; Fiorenzo Gaita; Gaetano Maria De Ferrari; Matteo Anselmino Journal: Medicina (Kaunas) Date: 2019-08-18 Impact factor: 2.430
Authors: Jane Chen; Bruce L Wilkoff; Wassim Choucair; Todd J Cohen; George H Crossley; W Ben Johnson; Luc R Mongeon; Gerald A Serwer; Lou Sherfesee Journal: Trials Date: 2008-04-03 Impact factor: 2.279
Authors: Yuichiro Yano; Philip Greenland; Donald M Lloyd-Jones; Emile G Daoud; Jodi L Koehler; Paul D Ziegler Journal: PLoS One Date: 2016-02-16 Impact factor: 3.240